Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: March 2007
-
By Donald Zuhn — On Wednesday, Cell Signaling Technology, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for its application entitled "Immunoaffinity Isolation of Modified Peptides from Complex Mixtures." A search of Public PAIR indicates that U.S. Application No. 10/175,486 will issue as Patent No.…
-
The folks at FedCirc.us have announced that a new search feature was implemented at the FedCirc.us site this morning. The new search feature gives readers access to FedCirc.us’ own Federal Circuit case summaries as well as to commentary and summaries from leading online commentators. We are flattered that FedCirc.us has decided to add the Patent Docs…
-
By Sherri Oslick — In a case testing the interplay between terminal disclaimers and patent term extensions under the Hatch-Waxman Act, the Federal Circuit, in affirming the judgment of the district court, held that patent term extensions could – nay should – be applied to terminally disclaimed patents, leaving Merck’s Hatch-Waxman extension for…
-
By Christopher P. Singer — MedImmune and sanofi pasteur announced today that they have entered into a licensing agreement concerning certain of MedImmune’s intellectual property relating to virus generation. Specifically, sanofi pasteur has licensed MedImmune’s "reverse genetics" technology which provides the ability to make viruses from DNA segments. Sanofi pasteur intends to use…
-
By Christopher P. Singer — In a March 29, 2007 press release Baxter International, Inc. announced that it will begin a Phase III clinical trial for an adjuvant-free vaccine against the H5N1 strain of influenza. The Phase III trial will be conducted in Europe in the first half of 2007, with results expected…
-
By Kevin E. Noonan — Indonesia fulfilled its earlier promise (see "Bird Flu Flying to WHO Again") to provide the World Health Organization (W.H.O.) with samples of H5N1 strains of influenza virus (otherwise known as "bird flu"), according to The New York Times (see "Indonesia to Send Bird Flu Samples, With Restrictions"). However,…
-
By Jason Derry — Sanofi-Aventis and Oxford BioMedica have announced an agreement under which the two companies will jointly develop and market TroVax® for treating and preventing cancer. TroVax® is a gene-based therapeutic cancer vaccine, and is currently in Phase III clinical trials as a treatment for renal cancer. Under the terms of…
-
By Kevin E. Noonan — To even the most casual observer of the Federal Circuit, the Supreme Court’s interest in the Court’s jurisprudence is startling. After fifteen years of giving scant attention to the Federal Circuit’s development of patent law, the Supreme Court has spent the last decade overturning what was thought to…
-
GTCbio will host a conference entitled "Litigation and Enforcement in the Biotech and Pharmaceutical Industry" on April 19-20, 2007 in San Francisco, CA. The conference is designed to address a wide variety of legal issues faced by biotech and pharmaceutical companies, including, among others, issues surrounding regulatory approval, advertising concerns, product liability, and intellectual property. …
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Dey, L.P. et. al. v. Sepracor, Inc.1:07-cv-02353; filed March 21, 2007 in the Southern District of New York Declaratory judgment of infringement…
Patent Docs 